122 related articles for article (PubMed ID: 9333147)
1. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
De Antoni A; Foli A; Lisziewicz J; Lori F
J Infect Dis; 1997 Oct; 176(4):899-903. PubMed ID: 9333147
[TBL] [Abstract][Full Text] [Related]
2. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
[TBL] [Abstract][Full Text] [Related]
4. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Winters MA; Shafer RW; Jellinger RA; Mamtora G; Gingeras T; Merigan TC
Antimicrob Agents Chemother; 1997 Apr; 41(4):757-62. PubMed ID: 9087484
[TBL] [Abstract][Full Text] [Related]
6. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
Edelstein RE; Nickerson DA; Tobe VO; Manns-Arcuino LA; Frenkel LM
J Clin Microbiol; 1998 Feb; 36(2):569-72. PubMed ID: 9466779
[TBL] [Abstract][Full Text] [Related]
8. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
12. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Sanne I; Smego RA; Mendelow BV
Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
[TBL] [Abstract][Full Text] [Related]
14. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
Bakshi RP; Hamzeh F; Frank I; Eron JJ; Bosch RJ; Rosenkranz SL; Cramer YS; Ussery M; Flexner C
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1360-5. PubMed ID: 18184078
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
[TBL] [Abstract][Full Text] [Related]
16. Seminal reservoirs during an HIV type 1 eradication trial.
Nunnari G; Leto D; Sullivan J; Xu Y; Mehlman KE; Kulkosky J; Pomerantz RJ
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):768-75. PubMed ID: 16218800
[TBL] [Abstract][Full Text] [Related]
17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
18. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
19. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
